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Abstract
Background: Quiescent/slow cycling cells have been identified in several tumors and correlated with therapy
resistance. However, the features of chemoresistant populations and the molecular factors linking quiescence to
chemoresistance are largely unknown.
Methods: A population of chemoresistant quiescent/slow cycling cells was isolated through PKH26 staining (which
allows to separate cells on the basis of their proliferation rate) from colorectal cancer (CRC) xenografts and
subjected to global gene expression and pathway activation analyses. Factors expressed by the quiescent/slow
cycling population were analyzed through lentiviral overexpression approaches for their ability to induce a dormant
chemoresistant state both in vitro and in mouse xenografts. The correlation between quiescence-associated factors,
CRC consensus molecular subtype and cancer prognosis was analyzed in large patient datasets.
Results: Untreated colorectal tumors contain a population of quiescent/slow cycling cells with stem cell features
(quiescent cancer stem cells, QCSCs) characterized by a predetermined mesenchymal-like chemoresistant
phenotype. QCSCs expressed increased levels of ZEB2, a transcription factor involved in stem cell plasticity and
epithelial-mesenchymal transition (EMT), and of antiapototic factors pCRAF and pASK1. ZEB2 overexpression
upregulated pCRAF/pASK1 levels resulting in increased chemoresistance, enrichment of cells with stemness/EMT
traits and proliferative slowdown of tumor xenografts. In parallel, chemotherapy treatment of tumor xenografts
induced the prevalence of QCSCs with a stemness/EMT phenotype and activation of the ZEB2/pCRAF/pASK1 axis,
resulting in a chemotherapy-unresponsive state. In CRC patients, increased ZEB2 levels correlated with worse
relapse-free survival and were strongly associated to the consensus molecular subtype 4 (CMS4) characterized by
dismal prognosis, decreased proliferative rates and upregulation of EMT genes.
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Conclusions: These results show that chemotherapy-naive tumors contain a cell population characterized by a
coordinated program of chemoresistance, quiescence, stemness and EMT. Such population becomes prevalent
upon drug treatment and is responsible for chemotherapy resistance, thus representing a key target for more
effective therapeutic approaches.
Keywords: Colorectal cancer, Chemotherapy resistance, Dormancy, Quiescence, Epithelial-to-mesenchymal
transition, Cancer stem cells
Background
The existence of cancer cells able to survive antineoplastic
drugs and to regenerate a local or distant tumor undermines
the effectiveness of cancer therapies. Drug resistance is
tightly connected to the presence of cancer stem cells
(CSCs) responsible for tumor progression, metastatization
and recurrence [1, 2]. Therapy-resistant cells with features
of stalled/delayed cycling have been identified in solid and
hematologic tumors including melanoma, glioblastoma, me-
dulloblastoma, leukemia, lung, breast, pancreatic and ovar-
ian cancer [3–14], suggesting that a population of quiescent/
slow proliferating cancer stem cells (QCSCs) may represent
an essential tool by which tumors resist to external chal-
lenges. Additionally, quiescence is typical also of tumor cells
present in the bloodstream, disseminated in the bone mar-
row or within lymph nodes (that altogether account for
minimal residual disease), suggesting that quiescent cells
represent a crucial therapeutic target [15]. In colorectal can-
cer (CRC), QCSCs were identified as cells able to reactivate
upon serial transplantation [16, 17], to survive chemother-
apy and to endure metabolic stress [18, 19]. Recently, two
distinct populations of slow cycling cells were identified in
CRC with different strategies. A label-retaining approach
identified dormant CRC cells as a differentiated population
with enhanced clonogenic capacity and high levels of Wnt
and Hedgehog signaling [20]. Differently, a histone 2B-GFP
(H2B-GFP) pulse-chase approach identified a population of
slow cycling cells characterized by expression of the TET2
dioxygenase and by enhanced chemoresistance [21]. The
quiescent/drug resistant state in solid tumors is tightly
linked to tumor heterogeneity and in particular to the ability
of cancer cells to undergo epithelial-to-mesenchymal transi-
tion (EMT), an epigenetic programme that crucially regu-
lates the stemness, chemoresistance and invasive ability of
cancer cells [22]. According to its pleiotropic effects on cel-
lular phenotype and function, EMT recruits a series of genes
with multiple functions in embryogenesis and carcinogen-
esis such as ZEB1, ZEB2, SNAI1, SNAI2 and TWIST1 [23].
Among these, ZEB2 has been shown to regulate epithelial
cell plasticity and proliferation, but also to balance stemness
and differentiation, standing as a master regulator of cell
state transitions [24–26]. Notably, ZEB2 was also recently
recognized as a factor implicated in drug resistance in CRC
through FBXW7 E3-ubiquitin ligase binding [27]. Moreover,
ZEB2 expression was associated with poor oncologic out-
come and distant recurrence, emerging as a new clinical bio-
marker in CRC [28]. In this study, we aimed to isolate and
characterize a population of cells with combined features of
quiescence and therapy resistance that is present in un-
treated colorectal tumors and becomes largely prevalent
upon chemotherapy treatment. In line with our previous
studies showing that PKH-retaining tumor cells were
endowed with higher tumorigenic capacity and chemother-
apy resistance [14, 16], we undertook an in-depth molecular
characterization of PKH26+ cells isolated from CRC xeno-
grafts through gene expression analysis and reverse-phase
proteomic arrays, providing for the first time a combined
picture of both transcriptional circuits and activated protein
pathways. New insights on the molecular factors that or-
chestrate quiescence programs will likely open new thera-
peutic avenues to eradicate non-proliferating cancer cells,
both in primary tumors and at premetastatic sites.
Materials and methods
Primary colorectal cancer cells and cell lines
Colorectal cancer (CRC) specimens were obtained from
patients undergoing surgical resection upon informed
consent and approval by the Sapienza-Policlinico Um-
berto I Ethical Committee (RIF.CE: 4107 17/10/2016).
Tissue samples were collected by a pathologist immedi-
ately after surgery, quickly washed 2–3 times in cold
phosphate buffered saline (PBS) and then transferred in
Dulbecco’s modified Eagle’s medium (DMEM; Thermo
Fisher Scientific) containing 3% penicillin-streptomycin-
amphotericin B solution (Lonza) until processing. For
tissue dissociation, CRC samples were first washed 3–4
times in PBS, then cut by forceps and/or scalpel in
pieces of approximately 0.5 mm or smaller. Fragments
were further washed twice by centrifugation at 150 g for
3 min, then incubated in DMEM with 1.5 mg/ml collage-
nase type II (Thermo Fisher Scientific) and 20mg/ml
DNAse (Roche Diagnostics) for 1 h at 37 °C under shak-
ing. The cell suspension was then filtered through a
100 μm nylon mesh and washed by 2 further centrifuga-
tion steps in DMEM. Pellets were resuspended in Colo-
rectal Cancer Spheroid Cells (CCSCs) medium [16]
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supplemented with 10mM nicotinamide, 1 mM Y-27632
(both from Sigma-Aldrich), 20 ng/ml human EGF and
10 ng/ml human basic fibroblast growth factor (both
from PeproTech). The resulting suspension was plated
in ultra-low attachment tissue culture flasks (Corning
Costar), and cultured in humidified atmosphere at 37 °C,
5% CO2. Every 2 to 3 days, half of the culture medium
was refreshed. Clusters of proliferating cells became evi-
dent after a variable length of time, ranging from 5 days
to 3 weeks. Cultures in which no proliferating clusters
were detected after 4 weeks were discarded. The result-
ing multicellular spheroid cultures were then passaged
weekly and used for in vitro and in vivo experiments
within the 12th passage. Genomic DNA was routinely
extracted from CCSCs and patient-matched nontumoral
tissues with the Dnasy Mini Kit (Qiagen) and used for
mutation analysis [29] and for Short Tandem Repeats
(STR) analysis. The latter was performed with the
AmpFlSTRIdentifiler Plus Kit (Applied Biosystems) and
used to generate a unique STR profile for each primary
CRC cell line, which was used to monitor purity of the
line over time and to confirm its matching with the ori-
ginal patient material. CCSCs were then routinely tested
for their ability to produce colon adenocarcinomas his-
tologically identical to the human tumors of origin when
injected into NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG)
mice (The Jackson Laboratory) as previously described
[29]. Primary CRC cells used in this study were obtained
from a 63 years old male CRC patient undergoing sur-
gery for G3 TNM IIIC right colon tumor and displayed
mutated APC, TP53, PI3KCA and KRAS and from a 65
years old female CRC patient undergoing surgery for G2
TNM IIA right colon tumor with mutated APC and
wild-type KRAS, TP53, PI3KCA. SW480 cells were pur-
chased from the American Type Culture Collection
(ATCC) and cultured in DMEM supplemented with 10%
heat-inactivated fetal bovine serum, 100 U/ml penicillin,
and 10 μg/ml streptomycin (Thermo Fisher Scientific) at
37 °C in a 5% CO2 atmosphere. Cultured cells (both pri-
mary and commercial lines) were routinely tested for
mycoplasma contamination with the PCR Mycoplasma
Test Kit (PanReac AppliChem).
Antibodies and reagents
Monoclonal antibodies against PROMININ-1 (AC133 epi-
tope both pure #130–090-423 used for immunofluores-
cence and biotinylated #130–090-664 used for flow
cytometry, 1:10) were obtained from Miltenyi Biotec.
Monoclonal anti-Ki67 (Dako, Agilent Technologies,
#M7240, 1:200) and polyclonal anti-Ki67 (Santa Cruz Bio-
technology, #sc-15,402, 1:200) were used for immunofluor-
escence. EpCAM-APC used for flow cytometry (#347200,
1:40) was from Becton Dickinson. Monoclonal anti-ZEB2
(#sc-271,984, 1:200) used for immunofluorescence was
from Santa Cruz Biotechnology. Anti-CRAF pS338 (MA1–
90087, 1:100) used for immunofluorescence was from
Thermo Fisher and anti-CRAF pS338 (#56A6, 1:1000) used
for western blot was from Cell Signaling Technology. Anti-
ASK1 pS83 (#3761, 1:1000), VIMENTIN (#5741),
CADHERIN-2 (#13116), SNAI1 (#3879), SNAI2 (#9585),
TCF8/ZEB1 (#3396) used for western blot were from Cell
Signaling Technology, while anti-CADHERIN-1 (#610181)
was from Becton Dickinson. Monoclonal anti-β-ACTIN
(#A5316, 1:10000) used for western blot was from Sigma-
Aldrich. Secondary mouse IgG, HRP-linked (#NA931, 1:
4000) and rabbit IgG, HRP-linked (#NA934V, 1:4000) were
from GE Healthcare Life Sciences. Secondary antibodies,
goat anti-mouse IgG Alexa Fluor®647-conjugated
(#A21235, 1:1000), goat anti-rabbit IgG Alexa Fluor®555-
conjugated (#A21428, 1:1000), streptavidin 647 (S32357, 1:
250), and 4′,6-diamidino-2-fenilindole (DAPI, #D1306, 100
nM) were obtained from Thermo Fisher Scientific. PKH26
(PKH26GL, Sigma-Aldrich) for cell membrane labeling was
used diluted 1:1000 and cells were stained following manu-
facturer’s instructions. ProLong Gold Antifade (#P7481)
was from Thermo Fisher Scientific. Mayer’s haematoxylin
(#MHS32) and Eosin (#HT110232) were from Sigma-
Aldrich and used according to the manufacturer’s protocol.
Etoposide (#E1383) and irinotecan (#I1406) were from
Sigma-Aldrich, oxaliplatin and 5-fluorouracil were from
Peviva. Agarose (SeaPlaque GTG agarose, #50111) was
from Lonza. Crystal violet (#C3886) was from Sigma-
Aldrich and used 0.1% in 10% MetOH. Triton X-100
(#1610407) was from Bio-Rad Laboratories and used at
0.1%. Stripping buffer was from Thermo Fisher Scientific
(#21059) and used according to the manufacturer’s proto-
col. Matrigel (Corning® Matrigel® Growth Factor Reduced
(GFR) Basement Membrane Matrix) was purcheased from
Corning (#354230).
Animal procedures
All animal procedures were performed according to the
Italian National animal experimentation guidelines
(D.L.116/92) upon approval of the experimental protocol
by the Italian Ministry of Health’s Animal Experimenta-
tion Committee (DM n. 292/2015 PR 23/4/2015). 6-
week-old female NOD-SCID mice from Charles River
Laboratories were used for PKH26 experiments and 6-
week-old female NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ
(NSG) mice (The Jackson Laboratory) were used for ex-
ogenous ZEB2 expression experiments. For PKH26 ex-
periments, 5 × 105 CCSCs were injected subcutaneously
in the flank of NOD/SCID mice, in 100 μl 1:1 PBS/
Matrigel (BD Biosciences). Tumors were measured twice
weekly by an external digital caliper, and volumes were
calculated using the following formula: π/6 x d2 x D,
where d and D represent shorter and longer tumor
measurements, respectively. Mice were grouped and
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sacrificed at different time point (1, 3, 6 weeks after in-
jection) for subsequent studies. For exogenous ZEB2 ex-
pression experiments, 104 CCSCs or SW480 cells
transduced with pLenti-GFP and pLenti GFP-ZEB2 were
injected subcutaneously in the flank of NSG mice as de-
scribed above. Drug treatments started when tumor vol-
ume reached 50–100 mm3. Mice were randomized in
control and treatment group and treated with 12,5 mg/
kg 5-fluorouracil and 5 mg/kg oxaliplatin intraperitone-
ally weekly. Control animals were treated with vehicle
only. Tumor growth was measured at the indicated time
points. Animals were euthanized according to the na-
tional Animal Welfare Guidelines.
Reverse-phase protein Array
Following FACS separation, CCSCs were promptly lysed
in 10 μl extraction buffer [50% 2X Tris-Glycine SDS
Sample Buffer (Life Technologies), 47.5% 1X with T-
PER reagent (Thermo Fisher Scientific and 2.5% Tris (2-
carboxyethyl) phosphine hydrochloride (TCEP) reagent
(Thermo Fisher Scientific)]. Lysates were boiled for 3
min and stored at − 80 °C until further processing. Prior
to printing on nitrocellulose slides (GRACE Bio-Labs
Inc.) via a robotic arrayer (Aushon Biosystems), samples
were thawed and boiled 3min. In order to increase the
amount of protein deposited on each slide, printing was
performed by using 5 depositions per spot and samples
were printed in technical triplicates. Reference standard
lysates, i.e. HeLa + Pervanadate (Becton, Dickinson and
Company), A431 + EGF (Becton, Dickinson and Company),
Jurkat + Etoposide (Cell Signaling Technology) and Jurkat +
Calyculin A (Cell Signaling Technology), were printed in
10-point decreasing mixtures of treated to untreated sam-
ples as procedural controls and as positive controls for anti-
body staining. Each reference standard curve was printed in
technical triplicate at a final concentration of 0.5mg/ml. A
selected subset of the printed microarray slides were stained
with Sypro Ruby Protein Blot Stain (Thermo Fisher Scien-
tific) to estimate sample total protein concentration and the
remaining slides were stored under desiccated conditions at
− 20 °C. Immediately before antibody staining, printed slides
were treated with 1X Reblot Mild Solution (Chemicon) for
15min, washed 2 × 5min with PBS and incubated for 2 h in
blocking solution containing 2% I-Block (Applied Biosys-
tems) and 0.1% Tween-20 in PBS. Immunostaining was car-
ried out using a tyramide-biotin signal amplification kit
(DAKO). Primary antibody binding was detected using a bi-
otinylated goat anti-rabbit IgG H+L (diluted at 1:7500; Vec-
tor Laboratories) or rabbit anti-mouse Ig (diluted at 1:10,
DAKO) followed by streptavidin-conjugated IRDye®-680LT
fluorophore (LI-COR Biosciences). Primary antibodies
underwent pre- and post-RPPA validation for single band
specificity by western blot using complex cellular lysates.
Negative control slides, incubated only with secondary
antibody were included in each staining run. All Sypro
Ruby and immunostained slides were scanned using a
Tecan Power Scanner™ (Tecan Group Ltd) at 5 μm reso-
lution. Acquired images were analyzed with MicroVigene
v5.2 (VigeneTech) for spot detection, local and negative
control background subtraction, replicate averaging and
total protein normalization. The “R” software packages ‘re-
shape2’, ‘ggplot2’, ‘coin’, ‘gplots’ and ‘shiny’ were used to
carry out slide quality control, internal standardization,
two-way hierarchical clustering (Euclidean distance and
Ward.D2 method), Kruskal-Wallis and Wilcoxon Rank
Sum non-parametric statistical tests (Benjamini & Hoch-
berg criterion was used for multiple comparisons adjust-
ment with an accepted false discovery rate of 0.05). A
detailed list of antibodies used for RPPA is available in
Additional file 1: Table S1.
Real-time PCR
Total RNA was extracted with TRIzol (Thermo Fisher
Scientific) following manufacturer’s instructions. 1 μg of
RNA was reverse transcribed with M-MLV reverse tran-
scriptase (Thermo Fisher Scientific) and 50 ng of cDNA
were used as template in the PCR reactions. Specific
probes used for ZEB2, MKI67, BMI1, β-ACTIN and
NANOG were all from Thermo Fisher Scientific
(Additional file 2: Table S2) and specific primers for
ZEB1, CDH1, VIMENTIN, SNAI1, SNAI2, CDKN1B,
(Additional file 3: Table S3) were from Sigma-Aldrich.
Normalization was performed using β-ACTIN as refer-
ence. RNA from xenografts derived from pLenti-GFP
and pLenti GFP-ZEB2-transduced cells was extracted
and reverse transcribed as described above. To analyze
the expression of cell cycle-associated genes TaqMan®
Array, Human Cyclins & Cell Cycle Regulation, Fast 96-
well (Thermo Fisher Scientific) was used following the
manufacturer’s instructions. Values were expressed in
terms of 2-ΔΔCt where ΔΔCT =ΔCTsample−ΔCTcalibra-
tor or ΔCt. ΔCt is the difference in threshold cycles be-
tween the specific RNA and reference gene amplicons
given by StepOne Plus Real-Time PCR software by nega-
tive correlation with an internal reference dye (ROX).
Human transcriptome array
PKH26+ and PKH26− xenograft-derived CCSCs were
FACS-sorted as described in the flow cytometry section
and processed with the HTA 2.0 Affymetrix array fol-
lowing the manufacturer’s instructions. The data matrix
having as rows (statistical units) and as columns (vari-
ables) of the 10 samples (5 PKH26+ and 5 PKH26−) was
analysed by means of Principal Component Analysis
(PCA) to single out an independent component allowing
for the complete partition of PKH26+ and PKH26− sam-
ples in the loading space [30]. The transcripts having the
highest absolute score in the discriminant component
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were identified. The replicated entries of genes (for
PKH26− samples: Homo sapiens piRNA piR-43,853
complete sequence, transfer RNA Gly (anticodon TCC),
transfer RNA Ile (anticodon AAT), transfer RNA Leu
(anticodon AAG), transfer RNA Leu (anticodon TAG),
transfer RNA Pro (anticodon AGG), transfer RNA Pro
(anticodon CGG); for PKH26+ samples: Homo sapiens
piRNA piR-31,233 complete sequence, Homo sapiens
piRNA piR-35,626 complete sequence, Homo sapiens
piRNA piR-37,799 complete sequence, Homo sapiens
piRNA piR-38,408 complete sequence, Homo sapiens
piRNA piR-53,527 complete sequence, Homo sapiens
piRNA piR-55,000 complete sequence, Homo sapiens
piRNA piR-57,434 complete sequence) were both se-
lected as conditions-related genes allow for a quality
proof of the results.
PKH26 staining
SW480 or CCSCs (the latter previously dissociated with
TrypLE Express, Thermo Fisher Scientific) were stained
for 2min at 37 °C with PKH26 (Sigma), then washed ex-
tensively with PBS. PKH26 staining was assessed by flow
cytometry and cells were used for subsequent experiments
only when positivity was ≥98%. For in vivo experiments
5 × 105 PKH26-stained cells were injected subcutaneously
in NSG mice, which were sacrificed at different times for
the detection of PKH26+ cells or at 3 weeks post-injection
for all the other experiments.
Lentiviral infection
CCSCs or SW480 cells were stably transduced with
pLenti-GFP (lentiviral vector with C-terminal GFP tag,
catalogue number PS100065) or pLenti GFP-ZEB2 (cata-
logue number RC215227L2) purchased from Origene
(Rockville, MD, USA).
Flow cytometry, cell cycle analysis and cell sorting
For flow cytometry experiments, xenografts derived from
PKH26-stained cells were cut into small pieces, washed
with ice-cold PBS, and subsequently digested with Try-
pLE express for 15 min at 37 °C with vigorous pipetting
every 5 min. Freshly isolated cells were stained with bio-
tinylated anti-PROMININ-1 and anti-EpCAM and spe-
cific secondary antibodies. 10 μg/ml 7-aminoactinomycin
D was used for dead cell exclusion. The cell cycle status
of CCSCs and SW480 xenograft cells transduced with
the pLenti-GFP vector or with pLenti-GFP-ZEB2 was
assessed by staining dissociated cells with 50 μg/ml pro-
pidium iodide dissolved in buffer 0.1% trisodium citrate,
9.65 mM NaCl, 0.1% Nonidet P40, and 200 μg /ml RNase
for 1 h at room temperature. Samples were analyzed
with a FACSCanto flow cytometer (Becton Dickinson)
equipped with a DIVA software. To obtain EpCAM+/
PKH26+ and EpCAM+/PKH26− or pLenti-GFP and
pLenti GFP-ZEB2 fractions, cells were sorted with a
FACSAria (Becton Dickinson).
Immunofluorescence
CCSCs were centrifuged at low speed on polylysine-
coated glass slides, whereas SW480 cells were grown dir-
ectly on glass slides. Cells were then fixed in 2% parafor-
maldehyde (PFA) for 15 min at room temperature and
permeabilized in 0.1% Triton X-100 for 5 min at RT
then, after two washes in PBS, they were incubated with
glycine 1M (Sigma-Aldrich) 1 h at room temperature.
Glycine was removed without washing and, after block-
ing in 3% BSA (Sigma-Aldrich)/3% FBS (Gibco)/PBS
(Sigma-Aldrich), cells were incubated overnight at 4 °C
with primary antibodies anti-Ki67, CRAF pS338 and
anti-ZEB2. After two washes in PBS, cells were incu-
bated with appropriate secondary antibodies in a buffer
containing DAPI, 3% BSA, 5 μg/ml RNAse (Roche)
diluited in PBS for 1 h at room temperature in the dark.
Subsequently, glasses were mounted with ProLong Gold
Antifade. Immunofluorescence staining of xenograft-
derived sections was performed as follows: sections were
fixed in 2% PFA for 15 min at room temperature,
washed two times in PBS and permeabilized in 0.1% Tri-
ton X-100 for 5 min at room temperature then incu-
bated overnight at 4 °C with primary antibodies anti
CRAF pS338, anti PROMININ-1, anti Ki67 and anti
ZEB2. After washing in PBS, sections were incubated
with a mixture of appropriate secondary antibodies and
DAPI as described above. SW480 cells were seeded 5 ×
104 cells/ml and treated after 24 h with etoposide 10 μM
or irinotecan 10 μM for 48 h. Cells were processed for
immunofluorescence as described above and stained with
anti-pCRAF, the appropriate secondary antibody and
DAPI for nuclear identification. Slides were analyzed at
room temperature on a FV-1000 confocal microscope
(Olympus) equipped with Ultraplan Apochromatic 60X
N.A.1.42 and 40X N.A. 1.30 oil immersion objectives and
acquired with the Olympus Fluoview software. The result-
ing images were not subjected to further processing.
Western blotting
Cultured cells or ~ 50mg pieces of frozen xenografts
were lysed in the appropriate volume of the respective
lysis buffer: for cultured cells we used 1% NP40 lysis buf-
fer (20 mM Tris HCl pH 7.2, 200 mM NaCl, 1% NP40),
while for xenograft tissues we used 10mM Tris pH8,
150 mM NaCl, 60 mM Octyl-β-Glucoside. Both buffers
were supplemented with protease inhibitor cocktail and
phosphatase inhibitor cocktails I and II (all from Sigma-
Aldrich). Tissues were homogenized with Pro 200 Kema
Keur (Pro Scientific Inc. Oxford) at maximum speed at
4 °C for 30 s. Lysate concentration was determined with
the Bradford assay (Bio-Rad Laboratories) and equal
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amounts of proteins were loaded on a 4–12% precast gel
(Thermo Fisher Scientific) and transferred to nitrocellu-
lose membranes (GE Healthcare Life sciences). Blots
were blocked with TBST 5% nonfat dry milk (Bio-Rad
Laboratories) and incubated overnight at 4 °C with pri-
mary antibodies diluted in TBST/BSA 5%, after 4 washes
in TBST then incubated for 45min with specific second-
ary HRP-conjugated antibodies diluted in TBST 5% nonfat
dry milk. Images were taken and analyzed with Bio-Rad
ChemiDoc Imagers (Bio-Rad Laboratories). For densitom-
etry quantification immunoblot signals were acquired with
ChemiDocMP (BioRad) and the relative intensity was
quantified with Image Lab software. Normalization was
performed using β-ACTIN as reference.
RNA interference
1.25 × 105 CCSCs or SW480 cells were seeded on six-
well plates in antibiotic-free culture medium and incu-
bated for 4 h at 37 °C in the presence of 320 nM ON-
TARGETplus SMARTpool non-targeting siRNA (D-
001810-01-055), human ZEB2 siRNA (L-006914-02-
0005) (Dharmacon/Thermo Scientific) and 5 μl Lipofec-
tamine 2000 (thermo fisher scientific). After 4 h the
transfection mixture was substituted with the appropri-
ate culture medium and cells were analyzed for cell via-
bility, gene and protein expression at the indicated times
Cell viability assay
The viability of CCSCs or SW480 cells was determined
by CellTiter-Glo luminescent cell viability assay (Pro-
mega) according to the manufacturer’s directions.
CCSCs and SW480 cells (2.5 × 103 per well) were seeded
in 96-well plates (three replicates per experimental
point) in the appropriate medium and incubated in a hu-
midified atmosphere at 37 °C, 5% CO2. For in vitro
chemotherapy treatment, cells were treated for 48 h with
10 μM 5-fluorouracil or 10 μM oxaliplatin. Lumines-
cence was detected with a DTX880 multimode micro-
plate reader (Beckman Coulter).
Statistical analyses
Statistical analyses were performed using GraphPad
Prism version 4.0 for Windows (GraphPad Software)
with non-paired double-tailed t test (after verifying nor-
mal distribution of the population with Shapiro–Wilk
test) or with one-way ANOVA where appropriate. Re-
sults are presented as the mean ± SD or mean ± SEM
where appropriate. Statistical significance is expressed as
*, P < 0.05, **, P < 0.01 and ***, P < 0.001. Statistical ana-
lysis of Affymetrix results and of Reverse Phase Prote-
omic Arrays (RPPA) are described in the specific
Supporting Methods sections and/or in the respective
figure legends. Principal Component Analysis was per-
formed by SAS version 8.1.
Results
Isolation and characterization of QCSCs responsible for
chemoresistance in colorectal tumors
Seminal studies on the dynamics of chemotherapy re-
sponse pointed to a rare cell population that remains la-
tent throughout the life of untreated tumors and
emerges only upon chemotherapy treatment [18]. We
ought to analyze such “pre-existing persisters” by using
the proliferation-sensitive dye PKH26, which incorpo-
rates into lipid membranes and is progressively lost dur-
ing subsequent cell divisions. In our previous studies, we
previously demonstrated that PKH+/high CRC cells pos-
sessed a higher tumorigenic potential as compared with
PKH−/low cells, indicating that the quiescent/slow cycling
fraction is enriched in cells with stemness features [16].
The PKH26 experimental system gave us the possibility
to identify cells that are quiescent/slow cycling from the
initial stages of tumor development and not just in a
given moment (as occurs instead with the H2B-GFP sys-
tem). First, we aimed to determine whether PKH26+
cells survived chemotherapy treatment. SW480 CRC
cells were stained with PKH26, then allowed to divide
for 11 days, after which chemotherapy treatment was
started. We monitored the percentage of PKH26+ cells
for two additional weeks, during which the positive
population decreased to 0.5% in the original culture but
increased to more than 90% in chemotherapy-treated
samples (Fig. 1a). Drug-treated samples consisted of ~
60% live cells after 2 weeks, as shown by 7-AAD staining
(Additional file 4: Figure S1a). This observation indicates
that cells selectively surviving chemotherapy are the
same cells that were quiescent/slow cycling in untreated
tumors and not cells that entered quiescence upon drug
treatment. Therefore, we focused our attention on cells
present in untreated tumors that are destined to survive
chemotherapy treatment and we undertook their
isolation and characterization. To do this, we used mo-
lecularly annotated 3D cultures of primary CRC cells
(thereafter called CCSCs, Colon Cancer Spheroid Cells)
that were previously shown by our group and others to
faithfully reproduce original patient tumors when inocu-
lated in immunecompromised mice [17, 29, 31]. PKH26-
stained and sorted CCSCs were inoculated into the
flanks of NSG mice and the percentage of PKH26+ cells
was monitored over time by flow cytometry (Fig. 1b and
c). At 3 weeks post-injection we isolated from tumor xe-
nografts EpCAM+/PKH26+ and EpCAM+/PKH26− cells
(Additional file 4: Figure S1b) that were used for further
characterizations. Flow cytometry analysis showed that
PKH26+ xenograft cells were negative for Ki67 and
expressed very high levels of PROMININ1, indicating a
stem cell phenotype (Additional file 4: Figure S1c and
d), in line with our previous observations [16]. In order
to investigate whether long-term quiescent cells were
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characterized by a specific pattern of gene expression,
we analyzed PKH26+ and PKH26− cells freshly isolated
from CRC tumor xenografts with the Affymetrix 2.0 hu-
man transcriptome array. The existence of a gene signa-
ture able to discriminate between the two populations
was investigated through a purely unsupervised data
driven approach suitable to identify small sets of bio-
logically relevant genes in an otherwise similar back-
ground [30]. Principal component analysis (PCA) of the
results showed a sharp distinction between profiles of
fast proliferating and quiescent/slow proliferating cells
emerging from the fourth PCA component (PC4) which,
although accounting for only 0.15% of gene expression
variability, nevertheless allowed for a perfect partition of
the loading component space into PKH26+ and PKH26−
areas (Fig. 1d). Setting two thresholds respectively at 6
and 10 standard deviation units from the mean (Fig. 1e),
we identified transcripts mostly affected by PC4 and
consequently more involved into PKH26+/ PKH26− dis-
crimination (detailed in Additional file 5: Table S4). The
great majority of transcripts differentially modulated in
PKH26+ and PKH26− cells did not correspond to struc-
tural genes but rather to post-transcriptional regulators
(microRNAs, small nucleolar RNAs, piwi-interacting
RNAs, long non-coding RNAs and tRNAs) (Fig. 1f and
Additional file 6: Table S5), indicating that the balance
between quiescence and proliferation relies on the fine
tuning of a basically similar transcription pattern.
Among the transcripts more expressed in QCSCs we
found the long non-coding RNA relative to the tran-
scription factor ZEB2 (zinc finger E-box binding homeo-
box 2), previously known for its involvement in EMT
and TGF-β-regulated processes [32–34]. Moreover, the
ZEB2 mRNA had a statistically significant score on PC4
(− 2,34, *P < 0.01). Therefore, we decided to explore the
expression and function of ZEB2 in CRC cells. We
confirmed the enrichment of ZEB2 mRNA in PKH26+
cells isolated ex vivo from tumor xenografts and in
chemotherapy-treated cells (Fig. 1g and h), while in
xenograft sections ZEB2-expressing areas overlapped
with PKH26+ areas (Fig. 1i). ZEB2 expression in PKH26+
tumor cells was accompanied by an increased expression
of CRC self-renewal factors BMI1 and NANOG [35, 36],
of EMT-related genes ZEB1, VIMENTIN, SNAI1 and
SNAI2, of cyclin-dependent kinase inhibitor 1B
(CDKN1B, encoding for p27Kip1) and by lower levels of
MKI67 and CADHERIN-1 (Fig. 1l), indicating that the
QCSCs population in colorectal tumors is characterized
by stemness and EMT features. In line with these obser-
vations, we analyzed CCSCs expressing the TOP-GFP
vector as a functional marker of β-catenin activity and a
surrogate marker of CRC stem cells [37]. Sorted CCSCs
with higher levels of TOP-GFP (and consequently of β-
CATENIN-dependent transcription) expressed higher
levels of ZEB2 (Fig. 1m), further supporting the stem-
ness of quiescent/slow cycling CRC cells.
Global pathway analysis shows the activation of
chemoresistance-related factors in QCSCs
Reverse-Phase Protein Array (RPPA) allows the simul-
taneous evaluation of phosphorylated, cleaved, or un-
modified proteins generating comprehensive profiles of
pathway activation in different cell or tissue samples [38,
39]. RPPA was used to compare PKH26+ and PKH26−
cells isolated ex vivo from CCSCs-derived tumor xeno-
grafts in order to obtain a broad picture of signaling
pathways modulated in these two populations. Three
matched pools of ex vivo PKH26+/PKH26− cells were ana-
lyzed with the antibodies reported in Additional file 1:
Table S1. Hierarchical clustering showed that two samples
of QCSCs had a massive down modulation of most path-
ways, particularly those involved in proliferation and bio-
synthesis (Fig. 2a). The third sample of quiescent cells
showed a down regulation of most pathways but a simul-
taneous upregulation of a small set of phosphoproteins (c-
Met, VEGFR2, c-Abl, SGK) (Fig. 2a), indicating the exist-
ence of multiple layers of quiescence-associated signals.
Nevertheless, principal component analysis (PCA) of RPPA
(See figure on previous page.)
Fig. 1 Untreated tumors contain chemotherapy-resistant quiescent cells with an EMT/stemness phenotype and increased ZEB2 levels. a SW480
cells were stained with PKH26, treated with 2,5 μM oxaliplatin (OXA) at day 11 and monitored by flow cytometry. FACS plots are shown in
Additional file 4. b FACS plots showing PKH26 positivity in CCSCs-derived tumors the day of injection (Day 0) and at 1/3/6 weeks. c Percentage of
PKH26+ cells (black line) in relation to tumor size (red line). Mean ± SD or SEM (tumors), n = 6 tumors/group. d Spatial representation of principal
component (PC) analysis with genes as rows (statistical units) and samples as columns (variables). n = 5 samples of 2 pooled tumors each. e
Numerical PC plot identifying genes with the highest absolute score in the discriminant component. A full list of transcripts modulated in PKH26+
versus PKH26− cells is reported in Additional file 5. f Categories of transcripts enriched in PKH26+versus PKH26− cells. Replicated entries are
reported in Materials and Methods. Transcripts categories are detailed in Additional file 6. g qRT-PCR analysis of ZEB2 in EpCAM+/PKH26+ versus
EpCAM+/PKH26− cells from CCSCs-derived xenografts. *P < 0.05 (two-tailed t test), mean ± SD, n = 3 pools of 6 tumors each. h qRT-PCR of ZEB2
expression in SW480 cells untreated (day 0) or treated with 2,5 μM oxaliplatin (OXA). Mean ± SD of 3 experiments. i Representative confocal
image of CCSCs-derived xenograft sections showing overlapping areas of ZEB2 (red) and PKH26+ (yellow) positivity. Scale bar 80 μm. l qRT-PCR of
xenograft-derived EpCAM+/PKH26+ versus EpCAM+/PKH26− cells. *P < 0.05, **P < 0.01 and ***P < 0.001 (two-tailed t test). Mean ± SD, n = 3 pools
of 6 CCSCs-derived tumors each. m qRT-PCR analysis of ZEB2 expression in TOP-GFP.mcherry negative (grey) and positive (purple) CCSCs sorted
from in vitro culture. Mean ± SD of 3 experiments
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results highlighted a molecular signature common to quies-
cent/slow proliferating CRC cells (Fig. 2b). Statistically sig-
nificant endpoints modulated in PKH26+ and PKH26− cells
(shown in detail in Additional file 7: Table S6) are summa-
rized in Fig. 2c, where QCSCs are sharply identified by in-
creased levels of CRAF S338 phosphorylation and ASK1
S83 phosphorylation. Importantly, pS338 CRAF and pS83
ASK1 have been individually implicated in protecting cells
from genotoxic insults [40–42], but they have also been
shown to act in concert by forming a chemoresistance-
promoting complex at mitochondria [43]. Due to the spe-
cific role of pCRAF in driving therapy resistance [41], we
assessed its expression in tumor xenografts, where it over-
lapped with PKH26+ and partially with PROMININ1+ areas
(Additional file 8: Figure S2a), and we confirmed that it is
actually upregulated in drug-treated CRC cells (Additional
file 8: Figure S2b). Fast proliferating PKH26− cells showed,
among others, an increased expression of phosphorylated
Akt, MEK1/2, mTOR (and downstream effectors p70S6K
and 4EBP1), GSK3, histone H3 and NDRG1 (Fig. 2c). The
latter is particularly interesting as it has been reported to in-
hibit EMT, stemness and metastasis and is related to a fa-
vorable prognosis in CRC patients [44]. In order to rule out
the possibility of chance correlations in the statistical ana-
lysis of RPPA results, we complemented data shown in
Fig. 2c with a further analysis having samples as variants
and protein endpoints as units. In fact, since the samples
differ only for a transient functional state (proliferative sta-
tus), they have a largely overlapping RPPA profile that
translates into a major principal component explaining the
major part (80%) of the among samples variance [45]. This
implies that discrimination of the two populations can only
start from the second component on ward, getting rid only
of a minor proportion of variance. That said, the loading
space allowed for a posteriori perfect discrimination among
PKH26+ and PKH26− samples as for Factor 2 (Additional
file 8: Figure S2c), which explains only 8,5% of total vari-
ance and represents a common regulatory pathway within
the same cell population. We observed a remarkable super-
position between the two analyses, as the large majority of
endpoints are identified as discriminants in both ap-
proaches (Additional file 8: Figure S2d). However, E-
Cadherin emerges from the second approach as one of the
endpoints most relevant for group discrimination, adding
further significance to the hypothesis that QCSCs tend to-
wards a mesenchymal state. In summary, our results
showed that the molecular diversity among fast proliferat-
ing and quiescent/slow proliferating CRC cells concentrates
around distinctive pathway profiles. Rapidly proliferating
cells possess high levels of proteins involved in biosyn-
thetic/metabolic pathways and are shifted towards an
epithelial-like and chemosensitive status, while QCSCs de-
press pathways related to cell cycle/biosynthesis/metabol-
ism and selectively upregulate factors involved in self
renewal, chemoresistance and EMT/metastatic ability
(Fig. 2d).
ZEB2, pCRAF and pASK1 are coexpressed upon
chemotherapy and coregulated in CRC cells
Having identified ZEB2, pCRAF and pASK1 as factors
upregulated in QCSCs, we asked whether their expres-
sion was increased upon chemotherapy and modulated
in a coordinated manner. First, we analyzed ZEB2,
pCRAF and pASK1 expression in chemotherapy-treated
cells and we observed a parallel increase of the three fac-
tors following 5-fluorouracil and oxaliplatin treatment
(Fig. 3a). Then, we investigated whether the expression
of pCRAF and pASK1 was mechanistically regulated by
ZEB2 by modulating ZEB2 levels with siRNA-mediated
silencing or lentiviral overexpression in either CCSCs or
SW480 cells and analyzing variations in pCRAF and
pASK1. Transient ZEB2 siRNA-mediated silencing
(Fig. 3b) induced a decrease in the levels of S338-
phosphorylated CRAF and S83-phosphorylated ASK1
(Fig. 3c), indicating that pCRAF and pASK1 lie dow-
stream of ZEB2 in the quiescence/chemoresistance pro-
gram. Exogenous expression of a lentiviral GFP-ZEB2
construct (Fig. 3d) increased the expression levels of
pCRAF and pASK1 (Fig. 3e) and resulted in enhanced
chemoresistance of both CCSCs and SW480 cells (Fig. 3f)
(See figure on previous page.)
Fig. 2 Reverse-phase proteomic analysis of quiescent/slow cycling xenograft cells. a Hierarchical clustering of RPPA results obtained on 3
EpCAM+/PKH26+ and EpCAM+/PKH26− cell samples isolated from CCSCs-derived tumor xenografts. Clusters, identified for either antibodies or
samples and based on optimal cut of dendrograms, are indicated by coloured bars adjacent to dendrograms. The values represented by the
heatmap correspond to normalized intensities of antibodies, standardized over the sample set analyzed (z score). n = 3 pools of 12 tumors each.
A list of RPPA antibodies and modulated endpoints are reported respectively in Additional file 1: Table S1 and Additional file 7: Table S6. b
Principal component analysis (PCA) of RPPA results showing that PKH26+ samples have a common molecular signature. c Volcano plot showing
the antilogarithm (base = 10) of the adjusted P value versus base 2 logarithm of the ratio between PKH26+ and PKH26− samples. Kruskal Wallis
test was performed for each RPPA analyte on the 3 samples stratified by PKH26 positivity. RPPA analytes where Kruskal Wallis test resulted in a
statistically significant (*P < 0.05) change between PKH26-stratified samples, underwent a further analysis by means of Wilcoxon signed-rank test.
All the resulting p values were adjusted for multiple comparisons using the Benjamini-Hochberg correction. d Schematic representation of
pathways that emerged from experiments described in Figs.1 and 2 as present in PKH26-negative fast proliferating cells (left, red area) or in slow
proliferating/quiescent cells (right, blue area). Phosphorylation sites are outlined in green when they result in protein activation, in red when they
inhibit protein function. Activated pathways are highlighted in colors while inhibited pathways are depicted in light grey
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Fig. 3 Coordinated expression and modulation of ZEB2, pCRAF and pASK1. a Left: immunoblot analysis of ZEB2, CRAF pS338, and ASK1 pS83 on
whole lysates of SW480 cells treated for 4 days with 5 μM 5-fluorouracil (5-FU) or 2,5 μM oxaliplatin (OXA). Glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) was used as a loading control. Right: quantification of immunoblot shown on the left. b qRT-PCR analysis of ZEB2 levels
in CCSCs (left panel) and SW480 (right panel) 24 h after siRNA-mediated silencing of ZEB2. ***P < 0.001 from two-tailed t test. Data of qRT-PCR are
the mean ± SD, n = 3. c Immunoblot analysis of ZEB2, CRAF pS338, and ASK1 pS83 on whole cell lysates 24 h upon siRNA-mediated silencing of
ZEB2 in CCSCs (left panel) and SW480 (right panel). The respective quantifications are shown on the right. d qRT-PCR analysis of ZEB2 levels in
CCSCs (left panel) and SW480 (right panel) transduced with empty pLenti-GFP (Vector) or with pLenti-GFP-ZEB2 (ZEB2) and sorted on the basis of
GFP expression. ***P < 0.001 from two-tailed t test. Data are the mean ± SD, n = 3. e Immunoblot analysis of ZEB2, CRAF pS338, and ASK1 pS83 on
whole lysates of CCSCs (left panels) and SW480 cells (right panels) transduced with pLenti-GFP (Vector) or with pLenti-GFP-ZEB2 (ZEB2) and
sorted as above. The respective quantifications are shown on the right. f Viability of CCSCs (left) and SW480 (right) transduced with pLenti-GFP or
pLenti-GFP-ZEB2, sorted on the basis of GFP expression and immediately treated for 48 h with 10 μM oxaliplatin (OXA) and 10 μM 5-fluorouracil
(5-FU). *P < 0.05 from two-tailed t test, n = 3. Data are the mean ± SD of three independent experiments
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shortly after cell transduction and sorting. At longer
times of culture, however, both CCSCs and SW480 cells
transduced with ZEB2 downregulated protein levels until
they reached those found in untreated cultures (Add-
itional file 9: Figure S3a), where ZEB2 expression is lim-
ited to rare Ki67-negative cells (Additional file 9: Figure
S3b). These results indicate that ZEB2 controls the levels
of pCRAF and pASK1 and that its levels are strictly reg-
ulated in CRC cells.
ZEB2 expression induces tumor transition towards a slow
growing chemoresistant state
To investigate the effects of ZEB2 overexpression in vivo
we inoculated freshly sorted ZEB2-transduced SW480
cells in the flanks of immunecompromised mice and an-
alyzed xenograft growth, cell cycle status and expression
of cell cycle-, EMT- and stemness-related genes. ZEB2-
overexpressing tumors grew significantly slower than
vector-transduced tumors (Fig. 4a, left panel) and dis-
played higher ZEB2 and lower Ki67 levels as compared
to vector-transduced controls (Fig. 4a, right panel). Ex
vivo cell cycle analysis showed that ZEB2-overexpressing
tumors contained an increased proportion of cells in the
G0/G1 phase of the cell cycle and a lower proportion of
cells in G2/M (Fig. 4b). Assessment of EMT and self-
renewal factors as determined by qRT-PCR showed that
ZEB2-overexpressing tumors had increased levels of
ZEB2 itself (but not ZEB1), VIMENTIN, SNAI1 and
SNAI2, decreased levels of CADHERIN1 and increased
expression of BMI1 and NANOG (Fig. 4c). Similar results
were obtained with CCSCs, with the difference that ZEB2-
transduced-tumors had a delayed appearance as compared
to vector-transduced tumors (Additional file 10: Figure
S4a-d). ZEB2-overexpressing tumors showed a modulation
of several cell cycle-related factors including CYCLINA1,
CYCLIND1, CDC2, CDC25A, HDAC9 and HDAC5 and,
importantly, a strong upregulation of TGFB2 (Fig. 4d), in
line with previous studies showing a specific role of TGFβ2
in dictating the dormancy of disseminated tumor cells [46].
Then, we investigated the expression of ZEB2/pCRAF/
pASK1 in vivo upon chemotherapy treatment. Vector- and
ZEB2-transduced SW480 cells were inoculated into NSG
mice and the resulting tumors were treated with oxaliplatin
plus 5-fluorouracil for 3 weeks. In vector-transduced tu-
mors, chemotherapy induced a growth slowdown associ-
ated to a strong increase of ZEB2, pCRAF and pASK1.
Chemotherapy-treated control tumors showed also a tran-
sition towards a hybrid epithelial-mesenchymal state, as
showed by the increased expression of SNAI1–2, ZEB1,
VIMENTIN and N-CADHERIN but concomitant high ex-
pression of E-Cadherin (Fig. 4e-g). ZEB2-overexpressing tu-
mors grew more slowly than controls and had a baseline
higher expression of pCRAF, pASK1 and EMT-related fac-
tors with decrease of E-CADHERIN, indicating a complete
EMT (Fig. 4e-g). In line with these observations, ZEB2-
overexpressing tumors were unaffected by chemotherapy
treatment and did not change either their slow growing rate
or the expression of EMT/chemoresistance factors upon
drug exposure (Fig. 4e-g). Altogether, these results identify
ZEB2/pCRAF/pASK1 as factors present in rare quiescent
cells in untreated tumors that are largely expressed upon
chemotherapy treatment, thus inducing tumor transition
towards an EMT/chemotherapy unresponsive state.
ZEB2 expression correlates with worse prognosis and
CMS4 in CRC patients
Finally, we explored the potential clinical relevance of
our findings by analyzing ZEB2 expression in a CRC
dataset composed of all fresh frozen tumor samples
compiled by the consensus molecular classification con-
sortium [47]. This set, for which consensus molecular
subtype (CMS) classification and in most cases stage is
available, was separated by TNM stage and analyzed for
ZEB2 expression, revealing a slight but non-significant
increase with progressing stage (Additional file 11: Fig-
ure S5). However, segregation of the patients into low
and high ZEB2 expression revealed a very significant in-
crease in recurrence rate in patients with high ZEB2 ex-
pression across all TNM stages (p < 0.001, n = 802)
(Fig. 5a). Importantly, the majority of the patients in our
dataset could be faithfully assigned to one of the four
CMSs, which have distinguishing molecular, biological
and clinical features [47]. Among these, CMS4 is typified
by high expression of mesenchymal genes, prominent
TGF-β activation, stromal infiltration and worse relapse-
free survival [47]. In agreement with our hypothesis that
ZEB2 drives an EMT-related and therapy-resistant CRC
phenotype we found a significantly increased expression
of ZEB2 in CMS4 (***P < 0.001, n = 2822) (Fig. 5b). Like-
wise, consistent with the association of ZEB2 with a qui-
escent/slowly proliferating state, MKI67 expression was
reduced in CMS4 as compared to the other CMSs
(***P < 0.001, n = 2822) (Fig. 5c).
Discussion
Increasing evidence indicates that a quiescent state is
tightly linked to drug resistance in cancer cells. How-
ever, due to their rareness and plasticity, quiescent
cancer cells remain mostly elusive and represent a chal-
lenging therapeutic target [15]. We previously demon-
strated that stem cells in CRC can be found both in the
fast proliferating (PKH26−/low) and in the quiescent/slow
proliferating (PKH26+/high) fraction, but PKH26high cells
are endowed with a higher tumorigenic potential [16].
Now, we demonstrate that quiescent/slow cycling cells
present in untreated CRC xenografts are the same cells
that resist chemotherapy treatment. Quiescent/slow cyc-
ling cells isolated from untreated CRC xenografts were
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characterized by combined features of stemness, che-
moresistance and EMT, indicating that quiescence arises
as a whole set of molecular traits covering multiple cel-
lular processes. In fact, the connection between stemness
and EMT was known since early studies by Mani et al.,
who demonstrated that normal and neoplastic mammary
cells that underwent EMT exhibit stem cell markers and
functional characteristics [48]. However, further studies
also highlighted the implication of quiescence as a fea-
ture of CSCs undergoing EMT. To cite a few, in breast
cancer Lawson and coworkers identified a metastatic cell
population characterized by the expression of stem cell-,
EMT-, pro-survival-, and dormancy-associated genes [9],
while in acute myeloid leukemia Ebinger et al. isolated a
subset of dormant stem cells with reversible properties
of quiescence and therapy resistance [5]. In CRC, we
found that PKH26+/ZEB2+ cells were characterized by
high levels of PROMININ1, by an increased expression
of self-renewal factors BMI1 and NANOG and by
elevated nuclear β-CATENIN (as detected with the
TOP-GFP assay), indicative of enhanced stem cell prop-
erties. Notably, ZEB2 overexpression in vivo was able to
recreate a QCSCs population with features of chemore-
sistance and EMT. Such phenotype was almost identical
to that developed by chemotherapy-treated xenografts,
with the difference that ZEB2+ tumors appeared to have
a more complete EMT (N-CADHERINhigh/E-CADHER-
INlow) as compared to chemotherapy-treated tumors (N-
CADHERINhigh/E-CADHERINhigh). However, different
EMT states are not surprising as they are typical of
CSCs populations with enhanced plasticity [15, 49].
Altogether, these observations suggest the existence of a
slow cycling/mesenchymal/stem population across dif-
ferent tumors which may share, at least in part, a com-
mon molecular signature. Therefore, exploring the
molecular features of the dormant/stem population will
be particularly relevant for the identification of pharma-
cological strategies aimed at eradicating chemoresistant
(See figure on previous page.)
Fig. 4 ZEB2 induces a transition towards a quiescent/slow cycling and mesechymal-like state in CRC xenografts. a Left: Xenograft volume of
SW480 cells transduced with pLenti-GFP (Vector, black line/triangles) or with pLenti-GFP-ZEB2 (ZEB2, red line/squares). Mean ± SEM, 6 tumors/
group. **P < 0.01 (two-tailed t test). Middle: representative confocal images of Vector- and GFP-ZEB2-transduced SW480 xenografts stained with
anti-ZEB2 (red) and anti-Ki67 (white) antibodies. Scale bar 60 μm. Right: quantification of Ki67-, ZEB2- and GFP-positive cells performed on 3 sets
composed of 5 fields/group. *P < 0.05 and **P < 0.01. Mean ± SD (two-tailed t test, n.s. = not significant). AU, arbitrary units. b Cell cycle analysis of
GFP+ cells from Vector- and ZEB2-transduced tumors. c qRT-PCR analysis of GFP+ cells from Vector- and ZEB2-transduced tumors, n = 3 pools of 2
tumor each. *P < 0.05 and **P < 0.01 (two-tailed t test). Mean ± SD. d mRNA levels of cell cycle genes in GFP+ cells from Vector- and GFP-ZEB2-
transduced tumors. Mean ± SD, n = 3. *P < 0.05 (two-tailed t test). e Volume of xenografts expressing pLenti-GFP (Vector, black line) or GFP-ZEB2
(ZEB2, red line), untreated or treated (Vector, gray line/triangles and ZEB2 yellow line/diamonds) with 5-fluorouracil plus oxaliplatin (5FU + OXA).
Mean ± SEM, 6 tumors per group. *P < 0.05 and **P < 0.01 from one-way ANOVA and Bonferroni post-tests. f Upper panels: immunoblot analysis
of ZEB2, CRAF pS338 and ASK1 pS83 on whole tumor lysates derived from SW480 xenografts. Lower panels: densitometry analysis of western
blots, n = 3, *P < 0.05, **P < 0.01 and ***P < 0.001 (two-tailed t test). g Left: immunoblot analysis of EMT-related proteins on whole xenograft
lysates. Every sample is a pool of 2 tumors. Right: densitometry analysis, n = 3, *P < 0.05, **P < 0.01 and ***P < 0.001 (two-tailed t test)
Fig. 5 Higher ZEB2 expression is linked to CMS4 and poor prognosis in colorectal tumors. a Kaplan Meier curve showing the relapse-free survival
of 802 CRC patients separated on the basis of ZEB2 expression (red, low expression and blue, high expression). ***P < 0.001 based on log-rank
test. b ZEB2 levels in CMS4 tumors as compared with CMSs 1–3. ***P < 0.001 based on one-way ANOVA, n = 2822. Outliers are depicted as
crosses. c MKI67 levels in CMS4 as compared with CMSs 1–3. ***P < 0.001 based on one-way ANOVA, n = 2822. Outliers are depicted as crosses.
Both the analysis of variance and the single post-hoc pairwise comparison in b and c are highly significant
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cells or alternatively at preventing their reactivation.
Drugs potentially able to target dormant tumor cells
may be directed against factors that play a role in
both EMT and quiescence, such as those implicated
in TGFβ signaling [50]. Among these, TGFβ2 was
identified as crucial for the induction of dormancy in
disseminated tumor cells [46] and emerged as highly
upregulated in ZEB2-overexpressing tumors. These
findings are also in line with the observation that
ZEB2 is highly expressed in CMS4 tumors, which are
also characterized by prevalent TGFβ activation [47].
A comprehensive characterization of pathways modu-
lated in quiescent CRC cells performed by RPPA
showed a downregulation of main proliferative/biosyn-
thetic/metabolic pathways together with an upregula-
tion of chemoresistance factors CRAF pS338 and
ASK1 pS83. Accordingly, CRAF phosphorylation in
S338 was recently demonstrated to trigger a kinase-
independent mechanism of DNA repair and thera-
peutic resistance [41]. Further underlining the tight
connection between dormancy and chemoresistance,
both ZEB2-overexpressing and chemotherapy-treated
tumor xenografts acquired increased pCRAF and
pASK expression, suggesting that this may represent a
common stem in the transition through an EMT/che-
moresistant state. The finding that ZEB2 is increased
in CMS4 is in line with a recent study reporting that
this subtype is characterized by methylation of
miR200 promoter regions and consequent increased
expression of EMT-related genes [51]. Indeed, the in-
creased ZEB2 (and decreased MKI67) expression de-
tected in CMS4 tumors could be influenced by the
abundant stromal infiltrate characteristic of this sub-
type, as stromal fibroblasts can also display a ZEB1+/
ZEB2+/miR200−/Ki67− profile [52]. In fact, the inter-
actions between tumor cells and stromal fibroblasts
have been shown to play a key role in defining poor-
prognosis CRC by exploiting TGFβ signaling to drive
an aggressive CSC-enriched phenotype [53]. It is
likely that both the stromal and the epithelial part of
CMS4 tumors contribute to the establishment of an
aggressive phenotype through an interplay of signals
orchestrated by TGFβ, resulting in refractoriness to
conventional and targeted therapies [53, 54]. This hy-
pothesis is corroborated by recent observations show-
ing that budding areas of the tumor, which are in
close contact with the surrounding stroma, are char-
acterized by down regulation of proliferation genes,
EMT and switching to CMS4 [55].
Conclusions
Altogether, our results point to a ZEB2/pCRAF/pASK
molecular signature involved in the determination of a
quiescent/slow proliferative state that identifies a subset
of cells present in baseline conditions and expanded
both upon drug treatment and in aggressive CRC sub-
types. The identification and characterization of quies-
cent drug-resistant CSCs may pave the way for future
therapeutic strategies aimed at neutralizing this specific
population in CRC.
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microscopy images of PKH26-positive areas (yellow) in xenograft sections
immunostained with anti-pCRAF S338 (green) and PROMININ1 (red). Scale
bar, 80 μm. b Representative confocal microscopy images of SW480 cells
treated for 48 h with 10 μM etoposide or 10 μM irinotecan and stained
with anti-pCRAF S338 antibody. Scale bar, 20 μm. c Spatial representation
of principal component (PC) analysis computed on a matrix having load-
ing values of the two components, Factor 1 and Factor 2 that discrimi-
nates among PKH26+ and PKH26− samples. Results obtained on three
PKH26+ versus PKH26− samples, n = 3 pools of 12 tumors each. d Spatial
representation of scores of components representing relative RPPA anti-
bodies values (Factor 1 and Factor 2). Results obtained on three PKH26+
versus PKH26− samples, n = 3 pools of 12 tumors each.
Additional file 9: Figure S3. Trends of ZEB2 overexpression in cultured
cells. a Percentage of GFP positivity in CCSCs (diamonds) or SW480
(circles) cells transduced with empty pLenti-GFP (Vector) or with pLenti-
GFP-ZEB2 (ZEB2) as assessed by flow cytometry for 5 weeks following len-
tiviral transduction and sorting (day 0). Graph shows the mean ± SD of
three independent experiments. b Representative confocal image of
CCSCs and SW480 cells transduced with GFP-ZEB2 and labeled with anti-
Ki67 at day 28 after sorting. Circles indicate rare ZEB2+ cells, which are
also Ki67−. Scale bar, 50 μm.
Additional file 10: Figure S4. In vivo effects of ZEB2 overexpression in
CCSCs. a Volume of xenografts derived from CCSCs transduced with
pLenti-GFP (Vector, black line/triangles) or with pLenti-GFP-ZEB2 (ZEB2,
red line/squares). Graph shows the mean ± SEM, 6 tumors/group. **P <
0.01 from two-tailed t test. b Left panels: representative confocal images
of xenograft sections derived from tumors obtained with primary cells
transduced with pLenti-GFP (Vector) and GFP-ZEB2 (ZEB2). Sections were
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stained with anti-Ki67 (red). Scale bar, 70 μm. Quantification (right panel)
was performed on 5 fields /group. *P < 0.05 from two-tailed t test. AU, ar-
bitrary units. c Cell cycle analysis of GFP+ cells FACS-isolated from Vector
and ZEB2-transduced tumors obtained with primary cells. d qRT-PCR ana-
lysis of the indicated transcripts in Vector- and ZEB2-transduced tumors
obtained with primary cells, n = 3. *P < 0.05 and **P < 0.01 from two-
tailed t test. n.s. = not significant by t test. Values are the mean ± SD.
Additional file 11: Figure S5. ZEB2 expression in TNM stages,
correlation with RFS and CMS in stage 2 CRC patients. ZEB2 transcript
levels in the indicated number of CRC patients across all TNM stages.
One-way ANOVA resulted in non-significant differences between stages.
Outliers are depicted as crosses. n = 1079.
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